MARX Biotech Co., Ltd.
MARX Biotech Co., Ltd. engages in the online retail of men's health food and cosmeceutical products. The company was founded in 2015 and is based in New Taipei City, Taiwan.
MARX Biotech Co., Ltd. (7731) - Net Assets
Latest net assets as of June 2025: NT$213.80 Million TWD
Based on the latest financial reports, MARX Biotech Co., Ltd. (7731) has net assets worth NT$213.80 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$733.01 Million) and total liabilities (NT$519.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$213.80 Million |
| % of Total Assets | 29.17% |
| Annual Growth Rate | 56.43% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 185.41 |
MARX Biotech Co., Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how MARX Biotech Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MARX Biotech Co., Ltd. (2021–2024)
The table below shows the annual net assets of MARX Biotech Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$251.25 Million | -14.25% |
| 2023-12-31 | NT$292.99 Million | +382.43% |
| 2022-12-31 | NT$60.73 Million | -7.44% |
| 2021-12-31 | NT$65.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MARX Biotech Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1285.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$126.50 Million | 50.35% |
| Other Components | NT$221.58 Million | 88.19% |
| Total Equity | NT$251.25 Million | 100.00% |
MARX Biotech Co., Ltd. Competitors by Market Cap
The table below lists competitors of MARX Biotech Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
A W FOOD SERVICES OF CANADA INC
TO:AW
|
$50.76 Million |
|
Lanvin Group Holdings Limited
NYSE:LANV
|
$50.81 Million |
|
Cross Timbers Royalty Trust
NYSE:CRT
|
$50.82 Million |
|
Meta Biomed Co. Ltd
KQ:059210
|
$50.83 Million |
|
Hushan Autoparts Inc.
TW:7736
|
$50.73 Million |
|
Karex Berhad
KLSE:5247
|
$50.72 Million |
|
Jin Air Co Ltd
KO:272450
|
$50.72 Million |
|
Jai Corp Limited
NSE:JAICORPLTD
|
$50.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MARX Biotech Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 292,991,000 to 251,248,000, a change of -41,743,000 (-14.2%).
- Net loss of 96,825,000 reduced equity.
- New share issuances of 50,000,000 increased equity.
- Other comprehensive income decreased equity by 2,020,000.
- Other factors increased equity by 7,102,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-96.83 Million | -38.54% |
| Share Issuances | NT$50.00 Million | +19.9% |
| Other Comprehensive Income | NT$-2.02 Million | -0.8% |
| Other Changes | NT$7.10 Million | +2.83% |
| Total Change | NT$- | -14.25% |
Book Value vs Market Value Analysis
This analysis compares MARX Biotech Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.63x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.00x to 10.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$0.48 | NT$5.24 | x |
| 2022-12-31 | NT$0.35 | NT$5.24 | x |
| 2023-12-31 | NT$1.68 | NT$5.24 | x |
| 2024-12-31 | NT$0.49 | NT$5.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MARX Biotech Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.66%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 2.91x
- Recent ROE (-38.54%) is below the historical average (-4.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 21.00% | 14.12% | 1.07x | 1.39x | NT$7.22 Million |
| 2022 | 4.66% | 2.56% | 1.07x | 1.70x | NT$-3.24 Million |
| 2023 | -4.41% | -4.46% | 0.73x | 1.35x | NT$-42.22 Million |
| 2024 | -38.54% | -15.66% | 0.85x | 2.91x | NT$-121.95 Million |
Industry Comparison
This section compares MARX Biotech Co., Ltd.'s net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $768,265,667
- Average return on equity (ROE) among peers: 11.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MARX Biotech Co., Ltd. (7731) | NT$213.80 Million | 21.00% | 2.43x | $50.74 Million |
| Arich Enterprise Co Ltd (4173) | $1.21 Billion | 4.16% | 2.90x | $27.84 Million |
| MedFirst Healthcare Services lnc (4175) | $910.56 Million | 12.40% | 2.44x | $32.54 Million |
| Great Tree Pharmacy Co Ltd (6469) | $185.19 Million | 18.25% | 0.64x | $209.14 Million |